Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Acquisitions & Divestments (2018 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 8 years of Change in Acquisitions & Divestments data on record, last reported at $99.0 million in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 16.78% year-over-year to $99.0 million; the TTM value through Dec 2025 reached $542.2 million, up 16.12%, while the annual FY2025 figure was $542.2 million, 16.12% up from the prior year.
  • Change in Acquisitions & Divestments reached $99.0 million in Q4 2025 per VRDN's latest filing, down from $140.3 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $171.4 million in Q1 2025 and bottomed at -$497000.0 in Q2 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $77.3 million, with a median of $75.1 million recorded in 2021.
  • Peak YoY movement for Change in Acquisitions & Divestments: soared 3276.95% in 2021, then plummeted 78.92% in 2022.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $22.8 million in 2021, then surged by 65.67% to $37.7 million in 2022, then soared by 172.76% to $102.8 million in 2023, then grew by 15.7% to $119.0 million in 2024, then decreased by 16.78% to $99.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $99.0 million in Q4 2025, $140.3 million in Q3 2025, and $131.5 million in Q2 2025.